No packages match

mvnma - Multivariate Network Meta-Analysis using Bayesian Methods

Tools to conduct Bayesian multivariate network meta-analysis providing - the single correlation coefficient model by Efthimiou et al. (2015) <doi:10.1093/biostatistics/kxu030>; - per-outcome treatment hierarchies using the surface under the cumulative ranking curve (SUCRA), the probability of best value, or median (or mean) ranks (Salanti et al., 2011) <doi:10.1016/j.jclinepi.2010.03.016>; - across-outcomes benefit-risk assessment using the VišeKriterijumska Optimizacija I Kompromisno Rešenje (VIKOR) method (Opricovic & Tzeng, 2004) <doi:10.1016/S0377-2217(03)00020-1>; - convergence checks using trace plots, density plots, or the R-hat statistic; - forest plots of treatment estimates, scatter plots of per-outcome rankings, Hasse diagrams (Carlsen & Bruggemann, 2014) <doi:10.1002/cem.2569> to visualize the partial order of the treatments across all outcomes.

Last updated

jagscpp

3.74 score 1 stars

mtrank - Ranking using Probabilistic Models and Treatment Choice Criteria

Estimation of treatment hierarchies in network meta-analysis using a novel frequentist approach based on treatment choice criteria (TCC) and probabilistic ranking models, as described by Evrenoglou et al. (2024) <DOI:10.48550/arXiv.2406.10612>. The TCC are defined using a rule based on the smallest worthwhile difference (SWD). Using the defined TCC, the NMA estimates (i.e., treatment effects and standard errors) are first transformed into treatment preferences, indicating either a treatment preference (e.g., treatment A > treatment B) or a tie (treatment A = treatment B). These treatment preferences are then synthesized using a probabilistic ranking model, which estimates the latent ability parameter of each treatment and produces the final treatment hierarchy. This parameter represents each treatments ability to outperform all the other competing treatments in the network. Here the terms ability to outperform indicates the propensity of each treatment to yield clinically important and beneficial effects when compared to all the other treatments in the network. Consequently, larger ability estimates indicate higher positions in the ranking list.

Last updated

2.70 score 1 stars 3 scripts 152 downloads

mvnma - Multivariate Network Meta-Analysis using Bayesian Methods

Tools to conduct Bayesian multivariate network meta-analysis providing - the single correlation coefficient model by Efthimiou et al. (2015) <doi:10.1093/biostatistics/kxu030>; - per-outcome treatment hierarchies using the surface under the cumulative ranking curve (SUCRA), the probability of best value, or median (or mean) ranks (Salanti et al., 2011) <doi:10.1016/j.jclinepi.2010.03.016>; - across-outcomes benefit-risk assessment using the VišeKriterijumska Optimizacija I Kompromisno Rešenje (VIKOR) method (Opricovic & Tzeng, 2004) <doi:10.1016/S0377-2217(03)00020-1>; - convergence checks using trace plots, density plots, or the R-hat statistic; - forest plots of treatment estimates, scatter plots of per-outcome rankings, Hasse diagrams (Carlsen & Bruggemann, 2014) <doi:10.1002/cem.2569> to visualize the partial order of the treatments across all outcomes.

Last updated

jagscpp

1.00 score